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ABSTRACT Lymphangioleiomyomatosis (LAM) is a rare disease of women. Decline in lung function is
variable, making appropriate targeting of therapy difficult. We used unbiased serum proteomics to identify
markers associated with outcome in LAM.
101 women with LAM and 22 healthy controls were recruited from the National Centre for LAM in the
UK. 152 DNA and serum samples with linked lung function and outcome data were obtained from
patients in the National Heart, Lung and Blood Institute LAM Registry in the USA. Proteomic analysis
was performed on a discovery cohort of 50 LAM and 20 control serum samples using a SCIEX SWATH
mass spectrometric workflow. Protein levels were quantitated by ELISA and single nucleotide
polymorphisms in GC (group-specific component) encoding vitamin D binding protein (VTDB) were
genotyped.
Proteomic analysis showed VTDB was 2.6-fold lower in LAM than controls. Serum VTDB was lower in
progressive compared with stable LAM (p=0.001) and correlated with diffusing capacity of the lung for
carbon monoxide (p=0.01). Median time to death or lung transplant was reduced by 46 months in those
with CC genotypes at rs4588 and 38 months in those with non-A-containing haplotypes at rs7041/4588
(p=0.014 and 0.008, respectively).
The VTDB axis is associated with disease severity and outcome, and GC genotype could help predict
transplant-free survival in LAM.
This article has supplementary material available from erj.ersjournals.com
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Introduction
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease characterised by lung cysts and lymphatic
abnormalities. The disease is almost exclusively restricted to women, of whom it affects around nine per
million, and can occur both sporadically and in those with tuberous sclerosis complex (TSC) [1, 2]. In LAM,
cysts progressively replace the lung parenchyma leading to recurrent pneumothorax and often respiratory
failure over a variable period of years [3]. Lymphatic obstruction leads to chyloptysis, chylous effusions and
ascites. Around half of patients with sporadic LAM and most with TSC-LAM also have angiomyolipomas, a
benign tumour, generally occurring in the kidneys [2]. The lungs and lymphatics of patients are infiltrated
by LAM cells: a clonal, metastatic cell with a combined smooth muscle and melanocyte phenotype
characteristic of perivascular epithelioid cell neoplasms [4]. LAM cells have biallelic TSC mutations [5]
which lead to hyperactivation of the mechanistic target of rapamycin (mTOR), a component of two
multiprotein complexes, controlling proliferation, migration, autophagy and metabolism [6].
Most women with LAM lose lung function at an accelerated rate with forced expiratory volume in 1 s
(FEV1) declining by 70–140 mL per year [7, 8]; however, some progress rapidly while others can remain
stable for many years [3, 9]. Treatment with mTOR inhibitors prevents loss of lung function in most with
progressive disease [8–10]. Recognising progressive disease in individuals with mild lung function
impairment is important, although generally requires multiple measurements over a prolonged period [7].
Markers of disease activity are therefore required to predict those at risk of loss of lung function to allow
treatment before this occurs. Furthermore, stratification of patients with active disease could reduce the
size, duration, cost and feasibility of phase II studies of new therapies.
A number of clinical and serum prognostic factors have been identified. Elevated serum vascular
endothelial growth factor (VEGF)-D is associated with both the presence of LAM [11] and more rapid loss
of lung function. Presentation with dyspnoea rather than pneumothorax and a response to bronchodilators
have been associated with worse outcomes [12–14], whereas post-menopausal status is associated with
slower lung function loss [7, 15]. Despite this, it is not possible to accurately predict prognosis within
individuals. Here, we used serum proteomics to identify proteins associated with the presence and severity
of LAM, and identified that changes in vitamin D binding protein (VTDB) and its gene, GC
(group-specific component), are associated with disease severity and survival in LAM.
Materials and methods
Patients and sample collection
101 women with LAM and 22 healthy control women were recruited between 2011 and 2016 from the
National Centre for LAM (Nottingham, UK) (figure 1). Ethical approval was obtained from the East
Midlands Research Ethics Committee (13/EM/0264). All subjects provided written informed consent. A
second cohort of 152 women with LAM recruited between 1998 and 2001 in the National Heart, Lung
and Blood Institute (NHLBI) LAM Registry (USA) was used for replication and to study long-term
survival [16] (figure 1). Baseline chest and abdominal computed tomography, serial lung function, serum,
and DNA at recruitment were obtained for all subjects. Clinical assessment, lung function and sample
analysis for both cohorts are described in the supplementary material. Due to duration of follow-up,
all-cause mortality or the need for lung transplant was only available for the NHLBI LAM Registry cohort
and was obtained by querying the US National Death Index (www.cdc.gov/nchs/ndi/index.htm) and the
United Network for Organ Sharing databases (https://unos.org/data). As data on the use of rapamycin was
not available for this cohort, outcome data were censored at 2010 before rapamycin was widely used for
the treatment of LAM in the USA.
Proteomics
70 serum samples (50 LAM and 20 controls) were analysed on a SCIEX (Warrington, UK) TripleTOF
6600 mass spectrometer hyphenated to an Eksigent nanoLC 425 system using the SCIEX SWATH mass
spectrometric workflow [17]. Tandem mass spectrometry (MS/MS) spectra were searched using
ProteinPilot version 5.0 (SCIEX) with the Swiss-Prot human database (www.uniprot.org; January 2015) at
1% false discovery rate with an identification focus on biological modifications. SWATH data were aligned
to library files in PeakView (SCIEX), uploaded and processed using the SCIEX OneOmics platform [18].
Full details are given in the supplementary material.
Serum protein quantification
Serum VTDB, α1-acid glycoprotein 1 (A1AG1) and VEGF-D were determined in the UK cohort using
Quantikine ELISA kits DVDBP0, DAGP00 and DVED00, respectively (R&D Systems, Abingdon, UK).
VTDB in the NHLBI LAM Registry was measured using Quantikine ELISA kit DVDBP0B (R&D Systems).
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Genotyping
DNA was extracted from whole blood using the Wizard Genomic DNA Purification Kit (Promega,
Southampton, UK). As GC genotype varies across populations, genetic analysis was confined to those of
European ancestry. 65 UK LAM samples and 168141 unrelated control women of European ancestry from
the UK Biobank (www.ukbiobank.ac.uk) were genotyped using the Axiom UK Biobank array (Affymetrix,
TABLE 1 Clinical data for cohorts studied
UK discovery cohort UK replication
cohort
UK
rapamycin-treated
group
USA NHLBI
cohort
Healthy
controlsAll Stable Progressive
Subjects n 50 26 24 27 24 152 22
Age years 50.6±10.9 50.9±11.8 50.3±10.0 49.4±13.9 46.4±9.7 45.4±9.0 35.0±11.7
Disease duration years 13.9±11.1 14.2±11.4 13.5±11.1 9.1±9.5 13.1±9.5 4.6±4.3 NA
Angiomyolipoma 72 77 67 55 54 NT NA
Lymphatic disease 16 15 17 23 25 NT NA
TSC 14 19 8 15 21 NT NA
Pneumothorax 48 50 46 40 46 NT NA
Post-menopause 34 42 25 30 25 48 NA
FEV1 % pred 68.9±20.6 76.4±18.9 60.8±19.5 77.4±23.4 46.7±14.8 74.1±27.5 NA
DLCO % pred 59.8±15.8 68.9±12.7 50.0±12.9 62.9±17.1 43.3±12.3 55.7±25.6 NA
VEGF-D pg·mL−1 1327±1187 985±833 1698±1405 1275±1527 1082±1257 NT 397±125
Data are presented as mean±SD (at recruitment) or % (present at any time in disease course), unless otherwise stated. NHLBI: National Heart,
Lung and Blood Institute; TSC: tuberous sclerosis complex; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for
carbon monoxide; VEGF: vascular endothelial growth factor; NA: not applicable; NT: not available for testing. Disease duration in the UK
lymphangioleiomyomatosis cohort was from first symptom to enrolment, while in the NHLBI cohort disease duration was from diagnosis to
enrolment. In the NHLBI cohort menopause was assumed if ⩾50 years of age.
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FIGURE 1 Enrolment and samples tested: recruitment and access to samples and lung function data in the
UK and the USA National Heart, Lung and Blood Institute (NHLBI) lymphangioleiomyomatosis (LAM) cohorts.
PFT: pulmonary function test; VTDB: vitamin D binding protein. The UK discovery cohort comprised 50 serum
samples from individuals with LAM, the UK replication cohort comprised 27 LAM serum samples and the
USA NHLBI LAM Registry cohort comprised 152 serum samples.
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High Wycombe, UK). Ancestry was determined from k-means clustering of the first two principal
components from the genome-wide single nucleotide polymorphism (SNP) data [19]. Women from the
NHLBI LAM Registry cohort were genotyped using KASP PCR genotyping (LGC Genomics. Hoddesdon,
UK) with ancestry obtained by questionnaire.
Statistical analysis
Proteins identified by proteomics were considered differentially expressed if they were ⩽−2 or ⩾2 log2 fold
different between groups with a confidence ⩾0.7 as described by LAMBERT et al. [18]. Welch’s t-test or the
Mann–Whitney U-test were used for categorical data; linear regression and Spearman’s correlation were
used for continuous data. GC allele frequencies for women with LAM and UK Biobank controls were
compared using Chi-squared tests [20]. Survival analyses were performed using Kaplan–Meier plots with
differences analysed by the Mantel–Cox log-rank test. Analyses were performed using Prism version 7
(GraphPad, La Jolla, CA, USA) and SPSS version 24 (IBM, Armonk, NY, USA).
Results
Discovery cohort and serum proteomics
The first 50 UK women with LAM enrolled who were not treated with an mTOR inhibitor and 20 healthy
control women formed the discovery cohort. The cohort was divided into more progressive and stable
disease based upon a retrospective loss of FEV1 of >50 mL per year over a mean±SD period of observation
of 11±4 years. Those with progressive disease had lower FEV1, diffusing capacity of the lung for carbon
monoxide (DLCO) and higher serum VEGF-D values, but were of similar age and disease duration as those
with stable disease (table 1).
MS of the 70 serum samples identified 126 proteins, including the serum proteins albumin, haemopexin,
acid glycoprotein, immunoglobulins, complement components, clotting factors, proteases and protease
inhibitors (supplementary table E1). VTDB levels were 2.6-fold lower (confidence 0.65) in LAM than
healthy control women (supplementary table E2). To identify markers of severity we compared the
proteomic profiles of those with stable and progressive disease. A1AG1 levels were 3.6-fold higher
(confidence 0.70) in those with progressive compared with stable disease. Comparison of pre- and
post-menopausal women with LAM did not identify differentially expressed proteins at the pre-specified
confidence level.
Serum protein quantification
MS findings were validated using ELISAs for VTDB and A1AG1. Consistent with the proteomic findings,
serum VTDB was lower in 50 women with LAM in the UK discovery cohort and 27 women with LAM in
the UK replication cohort than in controls (p=0.007 and p=0.002, respectively). For the 77 women in the
UK discovery (n=50) and replication cohorts (n=27) combined, VTDB was 273±96 µg·mL−1 in LAM and
347±92 µg·mL−1 in control women (p=0.002) (figure 2a). When assessed by ELISA, A1AG1 was higher in
women with LAM in the discovery and replication cohorts than control women (p=0.04 and p=0.0001,
respectively). A1AG1 was 910±478 µg·mL−1 for all women with LAM and 619±270 µg·mL−1 in control
women (p=0.004) (figure 2b).
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FIGURE 2 Serum vitamin D binding protein (VTDB) and α1-acid glycoprotein 1 (A1AG1) in
lymphangioleiomyomatosis (LAM) and healthy controls. a) Women with LAM had lower levels of serum VTDB
compared with healthy control women (p=0.002). b) Women with LAM had higher levels of serum A1AG1
compared with healthy control women (p=0.004).
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VTDB is associated with disease severity
VTDB was significantly lower in those with more progressive compared with more stable lung disease at
recruitment (progressive 221±89 µg·mL−1 versus stable 299±90 µg·mL−1; p=0.001) (figure 3a). VTDB level
was positively associated with percent predicted DLCO (p=0.01) but not forced vital capacity (p=0.09) or
FEV1 (p=0.23) (figure 3b–d). A1AG1 was higher in those with stable compared with progressive disease
(stable 1004±525 µg·mL−1 versus progressive 753±341 µg·mL−1; p=0.01) (supplementary figure E1), but
was not related to lung function. Levels of VTDB were not associated with age, age at diagnosis,
menopausal status, nature of presenting symptom, presence of tuberous sclerosis, angiomyolipomas,
lymphatic disease or serum VEGF-D level (data not shown). The distribution of VTDB was similar in the
77 untreated women and 24 women receiving treatment with rapamycin for LAM, whereas A1AG1 was
higher in the rapamycin-treated group (treated 1132±474 µg·mL−1 versus untreated 910±478 µg·mL−1;
p=0.031) (supplementary figure E2).
Association of GC genotypes with LAM and serum VTDB
As GC genotype varies according to ancestry, genetic analyses were restricted to the 65 individuals in the
UK and 145 individuals in the NHLBI LAM Registry cohorts of European origin. Two SNPs within GC at
rs7041 and rs4588 define the major GC haplotypes: 1) GC1F where rs7041 (G) and rs4588 (A), 2) GC1S
where rs7041 (T) and rs4588 (A), and 3) GC2 where rs7041 (G) and rs4588 (C). The allele frequencies at
these SNPs in the UK and NHLBI LAM Registry cohorts did not differ from control women in the UK
Biobank or each other (supplementary table E3). In both LAM cohorts, as in the general population,
serum VTDB was dependent on GC genotype (supplementary figure E3) [21].
Association of VTDB protein and genotype with outcome
From the UK cohort, 91 women with LAM had lung function measured over >1 year after enrolment (64
untreated and 27 receiving rapamycin for LAM). The mean period of observation was 19 months,
corresponding to 144 patient-years of observation. Within the NHLBI LAM Registry cohort, 136 women
with untreated LAM had lung function measured over >1 year after enrolment with a mean period of
observation of 40 months, corresponding to 500 patient-years of observation. Serum VTDB was not
associated with prospective change in lung function in either cohort (table 2).
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FIGURE 3 Vitamin D binding protein (VTDB) is associated with disease severity. LAM:
lymphangioleiomyomatosis; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital
capacity; FEV1: forced expiratory volume in 1 s. a) Lower levels of serum VTDB are associated with
progressive LAM compared with stable LAM (p=0.001). b) VTDB level is positively correlated with DLCO % pred
(p=0.01). c) VTDB is not associated with FVC % pred (p=0.09). d) VTDB is not associated with FEV1 % pred
(p=0.23).
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Within the NHLBI LAM Registry cohort, those with low serum VTDB, the AA genotype at rs4588 and
TT at rs7041 had the highest rates of loss of FEV1 and DLCO, although not significantly so (table 3). We
then examined the relationship of the VTDB axis with time to death or lung transplant in the NHLBI
LAM Registry cohort. Although time to death or transplant was not associated with serum VTDB level
(p=0.76) (figure 4a) or rs7041 genotype, there was an association with rs4588 genotype. Median time to
death or transplant for the AA or AC genotype at rs4588 was 150 months compared with 104 months for
CC (p=0.014) (figure 4b). Median time to death or transplant for all haplotypes with an A allele at rs4588
(including GC1F and GC1S haplotypes) was 150 months compared with 112 months for haplotypes with
no A allele present (including GC2; p=0.008) (figure 4c).
Discussion
We have shown for the first time that the VTDB axis is associated with both severity and outcome in
women with LAM. VTDB levels were associated with DLCO and disease activity at assessment. Those with
progressive disease, defined by a loss of FEV1 of >50 mL per year, tended to have lower levels of VTDB
than those with more stable disease with a loss of FEV1 of <50 mL per year, despite being matched for age
and other clinical manifestations. Haplotypes of GC were associated with the time to death or lung
transplant. As such, GC genotype is the first genetic host factor found to influence transplant-free survival
in LAM.
VTDB is a glycosylated α-globulin produced by the liver, kidneys, adipose tissue and neutrophils. Coded for
by the GC gene on chromosome 4q, two SNPs in exon 11, i.e. rs7041 (Glu416Asp) and rs4588 (Thr420Lys),
define the three major haplotypes of VTDB: GC1F (416Asp/420Thr), GC1S (416Glu/420Lys) and GC2
(416Asp/420Lys), with serum VTDB level related to these SNPs [21]. VTDB binds 25(OH)-vitamin D and
1,25(OH)2-vitamin D, although vitamin D levels are far exceeded by the transport capacity of VTDB.
Serum levels of VTDB and vitamin D are unrelated in many diseases studied, including chronic obstructive
pulmonary disease (COPD) [22]. The GC variants have differing affinities for vitamin D; the complexities
of the VTDB isoforms, vitamin D and their impact on lung disease are not yet clear [23].
TABLE 2 Prospective change in forced expiratory volume in 1 s (FEV1) and diffusing capacity of
the lung for carbon monoxide (DLCO) and relationship to vitamin D binding protein (VTDB)
UK cohort NHLBI cohort
Untreated p-value# Rapamycin p-value# Untreated p-value#
Subjects n 64 27 136
ΔFEV1 mL per year −32.6±111.2 NS 24.3±141.4 NS −94.7±96.2 NS
ΔDLCO mmol·min−1·kPa−1 per year −0.2±0.40 NS −0.17±0.23 NS −0.23±0.31 NS
VTDB µg·mL−1 273±96 281±105 255±53.4
Data are presented as mean±SD, unless otherwise stated. NHLBI: National Heart, Lung and Blood Institute.
#: p-value for Spearman’s correlation with serum VTDB. NS: nonsignificant.
TABLE 3 Relationship of vitamin D binding protein (VTDB) genotype with clinical features, serum VTDB and change in lung
function in the National Heart, Lung and Blood Institute Lymphangioleiomyomatosis (LAM) Registry cohort
rs4588 SNP rs7041 SNP
AA CA CC p-value TT GT GG p-value
Subjects n 11 46 74 25 57 48
Age at diagnosis years 37.4±6.7 42.1±9.9 40.6±9.2 NS 39.9±7.6 41.8±9.7 40.5±9.6 NS
Age at recruitment years 40.9±6.4 47.2±9.4 45.3±8.9 43.8±7.5 46.4±9.4 45.4±9.3
FEV1 % pred 88.0±21.0 78.8±25.2 72.9±29.4 NS 79.9±26.8 79.0±30.2 72.0±24.0 NS
DLCO % pred 58.3±17.5 59.5±22.5 57.0±29.3 NS 56.3±18.2 58.1±30.8 58.9±23.2 NS
VTDB µg·mL−1 220±36 245±57 266±52 0.022 233±43 250±57 270±53 0.026
ΔFEV1 mL per year −125±142 −78±81 −99±97 NS −135±126 −80±84 −94±94 NS
ΔDLCO mmol·min−1·kPa−1 per year −0.35±0.23 −0.21±0.36 −0.22±0.3 NS −0.26±0.27 −0.20±0.35 −0.26±0.27 NS
Data are presented as mean±SD for women with LAM of European ancestry, unless otherwise stated (data for forced expiratory volume in 1 s
(FEV1) % pred, diffusing capacity of the lung for carbon monoxide (DLCO) % pred, VTDB and age at recruitment were all at entry to the study;
ΔFEV1 and ΔDLCO are prospective changes from recruitment). Linear regression was used to model the relationship between genotype, clinical
factors and VTDB. NS: nonsignificant.
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The mechanism relating GC genotype and serum VTDB is also unknown. rs7041 and rs4588 are intronic
SNPs; neither are in linkage disequilibrium with known promotor or enhancer SNPs, nor are they known
to affect protein stability. Factors other than GC genotype, including epigenetics, may also influence serum
VTDB levels, as although serum VTDB is lower in women with LAM than controls, GC genotype in our
study was not different.
Our findings reflect the complexity of both the VTDB axis and LAM. We observed that lower serum VTDB
was associated with lower lung function and more active lung disease at presentation. As VTDB is not
associated with other aspects of the LAM phenotype, including the presence of angiomyolipoma or
lymphatic disease, it is likely that the VTDB axis is not related to LAM per se, but as in other lung diseases
may alter the tissue response to disease. Importantly, GC genotype was associated with time to death or lung
transplantation. The strongest effect was for the GC1F and GC1S haplotypes, which were associated with an
increase in median survival of >3 years. Interestingly, these and other GC variants associated with improved
survival were not those associated with the lowest serum VTDB levels. VTDB is a multifunctional protein
which may impact upon the response to lung damage in a number of ways. GC1F and GC1S are associated
with increased macrophage activation over GC2 [22], and increased macrophage activation may be protective
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FIGURE 4 Survival analysis for vitamin D binding protein (VTDB) level and GC (group-specific component)
genotype in the National Heart, Lung and Blood Institute Lymphangioleiomyomatosis Registry cohort.
a) Overall time to death or transplant did not differ with serum VTDB level (low (147–221 µg·mL−1), medium
(222–275 µg·mL−1) and high (276–413 µg·mL−1)) (p=0.76). b) Individuals with the AA or AC genotype at rs4588
had greater time to death or transplant than those with the CC genotype (p=0.014). c) Haplotypes with an A
allele at rs4588 (GC1F and GC1S) were associated with longer time to death or transplant (p=0.008).
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in LAM, either by enhancing protective neutrophil responses or enhancing the chemotactic effect of
complement-derived C5a [24, 25]. VTDB also acts as an actin scavenging protein and therefore has the
potential to influence disease by different mechanisms, including altered innate immunity and tissue repair.
Different GC haplotypes are already associated with susceptibility to lung disease, with GC1F being
associated with an enhanced risk of COPD over GC1S and GC2 [26].
These observations underscore the multiple potential functions of VTDB, and how these functions may be
related to genotype and the complex relationship with lung disease. The complexity of LAM, a
multisystem disease, is also likely to be important. For example, VTDB protein is associated with DLCO but
not FEV1, forced vital capacity or event-free survival. While FEV1 is generally used to study the natural
history of LAM, DLCO is usually impaired before FEV1 and may better reflect early parenchymal damage
in LAM, with loss of FEV1 occurring later due to loss of elastic recoil and premature airway closure
brought about by parenchymal damage. Pulmonary vascular disease, host defence, peripheral muscle
function and other processes potentially affected by VTDB function may also contribute to survival.
One of the strengths of our study was the use of an unbiased proteomic method that identified VTDB as a
protein of interest in LAM. The involvement of the vitamin D axis in other diseases associated with tissue
remodelling make our findings biologically plausible [27]. However, our study also has limitations, including
the low number of control samples, technical limitations and those inherent in studying rare diseases. First,
VTDB was one of only two proteins differentially expressed in the serum of women with LAM and the
proteomic methodology used did not identify other LAM markers such as VEGF-D. VEGF-D is expressed at
picomolar levels [28], whereas VTDB is present a micromolar levels, suggesting that only relatively abundant
serum proteins with robust differences between women with LAM and healthy controls could be detected
using this proteomic strategy. It is therefore likely that other potentially useful biomarkers remain
undiscovered. Consistent with this, A1AG1, also known as orosomucoid, the other protein linked to the
presence of LAM in our proteomic screen, is another relatively abundant plasma α-globulin, comprising 1–
3% of plasma proteins. As A1AG1 is an acute-phase protein, already recognised as a biomarker of overall
survival in many populations, we did not study it further [29]. As LAM is very rare, studying the disease
relies upon cohorts accumulated over longer periods of time. Although both cohorts studied used
protocol-driven assessments to capture key data including lung function, there are some differences in the
data available for these groups. Although the two cohorts used were similar in terms of age and lung
function, prospective change in lung function differed, probably due to the use of rapamycin in the UK
cohort resulting in reduced loss of FEV1. Conversely, due to time of recruitment, long-term survival prior to
rapamycin use can now only be studied in the NHLBI LAM Registry cohort. Current individuals with
progressive disease, including those in the UK cohort studied here, tend to be treated with rapamycin [10]
and longer periods of observation are needed to study the effect of the VTDB protein or genotype on
survival in women with LAM treated with rapamycin.
In conclusion, low levels of VTDB are associated with poor lung function in LAM and GC genotypes are
associated with long-term outcome. Our findings suggest that the VTDB axis is a host factor that may
protect against lung damage in LAM and could be of prognostic significance. Further studies are required
to validate our findings and understand how the VTDB isoforms modulate lung damage in LAM and
other diseases.
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